吡柔比星膀胱灌注联合化疗治疗晚期膀胱癌临床研究.docVIP

吡柔比星膀胱灌注联合化疗治疗晚期膀胱癌临床研究 　　[摘要] 目的 探析吡柔比星膀胱灌注联合化疗治疗晚期膀胱癌的临床效果。方法 整群==选取2013年4月―2015年2月来该院就诊的75例晚期膀胱癌患者，随机分为对照组37例和观察组38例。对照组患者单纯采用化疗；观察组患者则在此基础上加用吡柔比星膀胱灌注治之，连续治疗2个月。评价治疗前后患者的生活质量，计算有效率，观察治疗过程中的不良反应。结果 观察组患者的生活质量改善明显优于对照组患者，其与生活质量相关的角色、认知、感情、社会功能得分明显高于对照组（P0.05）。结论 吡柔比星膀胱灌注联合化疗治疗晚期膀胱癌疗效确切，利于提高患者的生活质量，副作用少，值得临床广泛推广。 　　[关键词] 吡柔比星；膀胱灌注；化疗；膀胱癌 　　[中图分类号] R737.14 [文献标识码] A [文章编号] 1674-0742（2015）09（b）-0053-03 　　[Abstract] Objective To investigate the clinical efficacy of treating the advanced bladder cancer with pirarubicin for bladder perfusion combined chemotherapy. Methods 75 patients with advanced bladder cancer admitted to our hospital from April 2013 to February 2015were randomly divided into control group of 37 cases and observation group of 38 cases. The patients in the control group were treated with chemotherapy； while those in the observation group were treated with pirarubicin for bladder perfusion combined chemotherapy for 2 months continuously. We evaluated the patients quality of life， calculated the efficiency and observed the adverse reaction in the process of treatment. Results The patients quality of life in the observation group was better than that in the control group， and the patients character， cognitive， emotional and social function score associated with quality of life in the observation group was higher than that in the control group（P0.05）. Conclusion The therapy has definite curative effect and less adverse reaction， which is beneficial to improving patients quality of life， therefore it is worth clinical popularizing widely. 　　[Key words] Pirarubicin； Bladder perfusion； Chemotherapy； Bladder cancer 　　膀胱癌是泌尿科临床常见的恶性肿瘤之一，每年世界范围内新发病例可达30万例，肿瘤死亡率位列第八，病痛的折磨及化疗药物引起的不良反应给患者的身心带来了极大的煎熬，严重影响患者的生活质量[1]。该研究者近年来着重研究晚期膀胱癌的诊治，该研究整群选取2013年4月―2015年2月来该院就诊的75例晚期膀胱癌患者，在探究临床疗效及安全性的同时更关注晚期患者生活质量的变化，临床擅长以吡柔比星膀胱灌注联合化疗对其进行治疗，效果满意，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　选取来该院就诊的经病理检查确诊为晚期膀胱癌患者75例为研究对象，随机分为对照组和观察组。对照组患者37例，其中男22例，女15例；年龄42～75岁，平均年龄（53.5±4.7）岁；III期者10例，